A Phase III, Randomized, Open Label Study Evaluating the Safety of Apixaban in Subjects With Cancer Related Venous Thromboembolism
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 17 Oct 2017
At a glance
- Drugs Apixaban (Primary) ; Dalteparin sodium
- Indications Venous thromboembolism
- Focus Adverse reactions
- Acronyms ADAM VTE trial
- 11 Oct 2017 Status changed from recruiting to active, no longer recruiting.
- 24 Aug 2017 Trial design of the study published in the Thrombosis and Haemostasis.
- 26 Jan 2017 Planned End Date changed from 1 Dec 2020 to 1 Nov 2018.